Literature DB >> 25525975

Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population.

Sanne Rasmussen1, Trine Holm Jensen, Susanne Lund Henriksen, Peter Fentz Haastrup, Pia Veldt Larsen, Jens Søndergaard, Dorte Ejg Jarbøl.   

Abstract

INTRODUCTION: Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gastrointestinal conditions with significant impact on the daily lives of individuals. The objective was to investigate the prevalence and overlap of the three conditions in a Western general population.
MATERIAL AND METHODS: A nationwide study of 100,000 individuals 20 years and above, randomly selected in the general population. A web-based questionnaire survey formed the basis of this study. Questions regarding FD and IBS were extracted from the ROME III adult questionnaire. Questions regarding GERD were developed based on the Montreal definition. Prevalence estimates for GERD, FD IBS were calculated in total and for each sex separately and for four age groups. A Venn diagram was constructed, illustrating the overlap between the three conditions.
RESULTS: The overall response rate was 52.2%. The prevalence of GERD, FD and IBS was 11.2%, 7.7% and 10.5%, respectively, and overlap between two or three of these conditions was seen among 6.5% of the respondents. Among individuals meeting the criteria of one or more of the conditions GERD, FD and IBS, 30.7% had overlap between two or all three conditions.
CONCLUSION: GERD, FD and IBS are common conditions in the general population and the overlap between these conditions is also quite common. When diagnosing patients with GERD, FD and IBS, physicians should keep in mind that these patients could be suffering from more than one of these conditions.

Entities:  

Keywords:  ROME III; functional dyspepsia; gastroesophageal reflux disease; irritable bowel syndrome; overlap; population-based study; the Montreal definition

Mesh:

Year:  2014        PMID: 25525975     DOI: 10.3109/00365521.2014.983157

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  26 in total

1.  Hypnotherapy for Esophageal Disorders.

Authors:  Megan E Riehl; Laurie Keefer
Journal:  Am J Clin Hypn       Date:  2015-07

2.  The challenges of evolving Rome criteria for functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

Review 3.  Neuroimmune Cross Talk in the Gut. Neuroendocrine and neuroimmune pathways contribute to the pathophysiology of irritable bowel syndrome.

Authors:  Dervla O'Malley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-10-13       Impact factor: 4.052

4.  Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD.

Authors:  Nicola de Bortoli; Leonardo Frazzoni; Edoardo V Savarino; Marzio Frazzoni; Irene Martinucci; Aleksandra Jania; Salvatore Tolone; Michele Scagliarini; Massimo Bellini; Elisa Marabotto; Manuele Furnari; Giorgia Bodini; Salvatore Russo; Lorenzo Bertani; Veronica Natali; Lorenzo Fuccio; Vincenzo Savarino; Corrado Blandizzi; Santino Marchi
Journal:  Am J Gastroenterol       Date:  2016-09-20       Impact factor: 10.864

5.  The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting.

Authors:  N A Koloski; M Jones; J Hammer; M von Wulffen; A Shah; H Hoelz; M Kutyla; D Burger; N Martin; S R Gurusamy; N J Talley; G Holtmann
Journal:  Dig Dis Sci       Date:  2017-05-27       Impact factor: 3.199

6.  British Society of Gastroenterology guidelines on the management of functional dyspepsia.

Authors:  Christopher J Black; Peter A Paine; Anurag Agrawal; Imran Aziz; Maria P Eugenicos; Lesley A Houghton; Pali Hungin; Ross Overshott; Dipesh H Vasant; Sheryl Rudd; Richard C Winning; Maura Corsetti; Alexander C Ford
Journal:  Gut       Date:  2022-07-07       Impact factor: 31.793

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 8.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 9.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

10.  Multiple functional gastrointestinal disorders linked to gastroesophageal reflux and somatization: A population-based study.

Authors:  R S Choung; G Richard Locke; C D Schleck; A R Zinsmeister; N J Talley
Journal:  Neurogastroenterol Motil       Date:  2017-03-03       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.